Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Hematopoietic stem cells: New results to be presented at the 18th Congress of the EHA

During ageing, this fine-tuned regulatory network may become altered, leading to abnormal HSC regulation. The functional quality of HSCs decreases with age partly due to an accumulation of damaged DNA, leading to an increased incidence of hematological malignancies.

Read more

Health data

Health data plays a substantial role in the European Union’s strategic, legislative, and funding initiatives in the health domain.

Read more

A brand new EHA website!

You may already have noticed the new EHA look & feel.  We are proud to share it with you already.  We are currently migrating all our pages and related information.

Read more

Enjoy Amsterdam like a Local

EHA24 is just around the corner, and we could not be more excited about the Congress program (especially the YoungEHA track – great science, interesting discussions, and food for thought are waiting for you)! As attending the Congress is also…

Read more

Abstract & Case Report submission

Late-breaking case report submission is now closed.

Read more

Regulation on Health Technology Assessment

The Regulation on Health Technology Assessment (HTAR) was proposed by the European Commission in 2018. It was formally adopted in December 2021 and will apply from January 2025.

Read more